Press Releases OBI Pharma, Inc.

Equities

4174

TW0004174008

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-13 EDT			5-day change	1st Jan Change
61.3 ^TWD	+0.16%		+0.49%	-11.67%

05-10	Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau	CI
03-26	OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform	03-18	GL
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform	03-18	AQ
Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992	01-09	AQ
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992	01-03	GL
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992	01-03	AQ
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer	23-06-02	GL
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy	23-04-10	GL
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy	23-04-10	AQ
OBI Pharma : Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to US FDA	22-08-12	PU
OBI Pharma : Announcement of amendment of the Company's 2021 Annual Report	22-08-11	PU
OBI Pharma : Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons	22-08-08	PU
OBI Pharma : Announcement that the cumulative reduction of shareholding in major subsidiary, AP Biosciences, has reached more than 10%	22-08-08	PU
OBI Pharma : forfeits subscription of AP Biosciences’ cash capital increase, distributes rights to its shareholders and sets target date	22-08-08	PU
OBI Pharma : The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders	22-08-08	PU
OBI Pharma : The Company's Board of Directors approved the amendment of 2022 Restricted Stock Awards Issuance Rules	22-08-08	PU
OBI Pharma : BOD resolved employees and amount granted for the first issuance of RSU and authorized the decision of record date to the Chairman	22-08-08	PU
OBI Pharma : Announcement of the Consolidated Financial Statements for the second quarter of 2022 were approved by the Board of Directors	22-08-08	PU
OBI Pharma : Announcement on behalf of subsidiary, Obigen Pharma Inc., that BOD resolved the Term Sheet for licensing of OBI-858 in China	22-07-21	PU
OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs	22-07-05	GL
OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs	22-07-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OBI Pharma, Inc.

Equities

4174

TW0004174008

Press Releases

Filters